SynthesisThe Korean journal of internal medicine2019

Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis.

Hyo Young Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.